H H Lundbeck A-S
H
Cerrado
41.58 -0.57
Resumen
Variación precio
24h
Mínimo
41.5
Máximo
41.82
Ingresos | -1.7B -27M |
|---|---|
Ventas | -465M 5.8B |
P/B Media del Sector | 13.386 51.415 |
BPA | 0.94 |
Rentabilidad por dividendo | 2.67 |
Margen de beneficios | -0.464 |
Empleados | 5,039 |
EBITDA | 130M 1.8B |
Rentabilidad por dividendo Media del Sector | 2.67% 2.34% |
|---|
Capitalización Mercado | 1.5B 42B |
|---|---|
Apertura anterior | 42.15 |
Cierre anterior | 41.58 |
H Lundbeck A-S Gráfico
Resultados pasados no son un indicador fiable de resultados futuros.
Noticias Relacionadas
Comparación entre iguales
Cambio de precio
H Lundbeck A-S previsión
Finanzas
Gastos de venta y administración
Gastos operativos
Beneficio antes de impuestos
Ventas
Coste de ventas
Beneficio bruto de ventas
Gasto por intereses de deuda
EBITDA
Beneficio operativo
$
Acerca de H Lundbeck A-S
H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company's principal products include Abilify Maintena/Abilify Maintena for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat MDD and schizophrenia. It also provides Azilect for treating Parkinson's disease; Cipralex/Lexapro for depression; Ebixa to treat dementia; Onfi for epilepsy; Sabril for the treatment of refractory complex partial seizures and infantile spasms; Xenazine for chorea; Deanxit for depression; Cipramil for depression and anxiety; and Cisordinol to treat psychosis. The company sells its products primarily to distributors of pharmaceuticals, pharmacies, and hospitals. It has a partnership collaboration with Otsuka Pharmaceuticals Co., Ltd.; and collaboration with Alloy Therapeutics, Inc. for the discovery of novel biologics therapies. The company was founded in 1915 and is headquartered in Valby, Denmark.
